Abstract
The phenanthroindolizidine and phenanthroquinolizidine alkaloids, typified by tylophorine and cryptopleurine, are a family of plant-derived small molecules with significant therapeutic potential. The plant extracts have been used in herbal medicine and the isolated compounds have displayed a range of promising therapeutic activity such as antiameobicidal, anti-viral, anti-inflammatory and anti-cancer activity. Despite their therapeutic protential, no compounds in this class have fully passed clinical trials. Drawbacks include low in vivo anti-cancer activity, central nervous system toxicity and low natural availability. A number of biological effects of these compounds, such as protein and nucleic acid synthesis suppression, have been identified, but the specific biomolecular targets have not yet been identified. Significant effort has been expended in the synthesis and structure-activity-relationship (SAR) studies of these compounds with the hope that a new drug will emerge. This review will highlight important contributions to the isolation, synthesis, SAR and mechanism of action of the phenanthroindolizidine and pheanthroquinolizidine alkaloids.
Current Bioactive Compounds
Title: Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy
Volume: 5 Issue: 1
Author(s): Sherry R. Chemler
Affiliation:
Abstract: The phenanthroindolizidine and phenanthroquinolizidine alkaloids, typified by tylophorine and cryptopleurine, are a family of plant-derived small molecules with significant therapeutic potential. The plant extracts have been used in herbal medicine and the isolated compounds have displayed a range of promising therapeutic activity such as antiameobicidal, anti-viral, anti-inflammatory and anti-cancer activity. Despite their therapeutic protential, no compounds in this class have fully passed clinical trials. Drawbacks include low in vivo anti-cancer activity, central nervous system toxicity and low natural availability. A number of biological effects of these compounds, such as protein and nucleic acid synthesis suppression, have been identified, but the specific biomolecular targets have not yet been identified. Significant effort has been expended in the synthesis and structure-activity-relationship (SAR) studies of these compounds with the hope that a new drug will emerge. This review will highlight important contributions to the isolation, synthesis, SAR and mechanism of action of the phenanthroindolizidine and pheanthroquinolizidine alkaloids.
Export Options
About this article
Cite this article as:
Chemler R. Sherry, Phenanthroindolizidines and Phenanthroquinolizidines: Promising Alkaloids for Anti-Cancer Therapy, Current Bioactive Compounds 2009; 5 (1) . https://dx.doi.org/10.2174/157340709787580928
DOI https://dx.doi.org/10.2174/157340709787580928 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pancreatic Cancer and Personalized Medicine: Can Genomics Facilitate Early Diagnosis or Improve Therapeutic Outcomes?
Current Pharmacogenomics and Personalized Medicine The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives
Current Topics in Medicinal Chemistry Epigenetic Therapies and Potential Drugs for Treating Human Cancer
Current Drug Targets Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology A New Synthesis for Acacetin, Chrysoeriol, Diosmetin, Tricin and Other Hydroxylated Flavones by Modified Baker-Venkataraman Transformation
Letters in Organic Chemistry Genomics-Based Identification of Molecular Mechanisms behind the Cancer Preventive Action of Phytochemicals: Potential and Challenges
Current Pharmaceutical Biotechnology Editorial:[Special Issue: Post-Translational Proteomics and its Application (Guest Editor: Qing-Yu He)]
Current Proteomics Serum Carboxypeptidase N1 Serves as a Potential Biomarker Complementing CA15-3 for Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: An Up-Date of Olive Oil and Bioactive Constituents in Health: Molecular Mechanisms and Clinical Implications (Executive Guest Editor: Catalina Alarcon de la Lastra Romero)]
Current Pharmaceutical Design Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery
Current Cancer Drug Targets Enzymes To Die For: Exploiting Nucleotide Metabolizing Enzymes for Cancer Gene Therapy
Current Gene Therapy Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Current Drug Targets Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science Melatonin, Immune Function and Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Survey of Computational Algorithms for MicroRNA Target Prediction
Current Genomics Artificial O2 Carriers: Status in 2005
Current Pharmaceutical Design DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets
Current Medicinal Chemistry